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Although type-2–induced (T2-induced) epithelial dysfunction is likely to profoundly alter
epithelial differentiation and repair in asthma, the mechanisms for these effects are poorly
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orchestrating epithelial cell fate in response to T2 stimuli has not previously been
investigated. Levels of a sialylated MUC4b isoform were found to be increased in airway
specimens from asthmatic patients in association with T2 inflammation. We hypothesized
that IL-13 would increase sialylation of MUC4b, thereby altering its function and that the b-
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with elevated T2 biomarkers. ST6GAL1-induced sialylation of MUC4b altered its lectin
binding and secretion. Both ST6GAL1 and MUC4b inhibited epithelial cell proliferation
while promoting goblet cell differentiation. These in vivo and in vitro data provide strong
evidence for a critical role for ST6GAL1-induced sialylation of MUC4b in epithelial
dysfunction associated with T2-high asthma, thereby identifying specific sialylation
pathways as potential targets in asthma.
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Introduction
Asthma is a complex heterogeneous disease in which type-2 (T2) immune-associated goblet cell hyperplasia 
and hypersecretion of  mucins are considered clinically important pathophysiologic features (1–3). Mucins 
are a large multifunctional family of  heavily N- and O-glycosylated proteins whose primary functions are to 
protect and lubricate epithelial surfaces. However, changes in glycosylation of  mucins could also affect their 
function, thereby affecting epithelium homeostasis and contributing to disease (4).
Glycosylation is an enzymatic cotranslational and posttranslational protein modification, which 
attaches glycans to proteins or lipids on specific sites in the rough ER (5). There are 5 major types of  
glycosylations; N- and O-linked are most common. N-linked glycans, in particular, are important for 
glycoprotein secretion, folding and stability, and cell-cell and cell-extracellular matrix attachments (6, 7) 
as well as receptor-ligand interactions of  relevance to cell signaling (8). Some of  N-glycan moieties are 
capped with sialic acids (a 9-carbon monosaccharide) at the terminal end (9).
Although type-2–induced (T2-induced) epithelial dysfunction is likely to profoundly alter epithelial 
differentiation and repair in asthma, the mechanisms for these effects are poorly understood. A role 
for specific mucins, heavily N-glycosylated epithelial glycoproteins, in orchestrating epithelial cell 
fate in response to T2 stimuli has not previously been investigated. Levels of a sialylated MUC4β 
isoform were found to be increased in airway specimens from asthmatic patients in association 
with T2 inflammation. We hypothesized that IL-13 would increase sialylation of MUC4β, thereby 
altering its function and that the β-galactoside α-2,6-sialyltransferase 1 (ST6GAL1) would regulate 
the sialylation. Using human biologic specimens and cultured primary human airway epithelial cells 
(HAECs),we demonstrated that IL-13 increases ST6GAL1-mediated sialylation of MUC4β and that 
both were increased in asthma, particularly in sputum supernatant and/or fresh isolated HAECs 
with elevated T2 biomarkers. ST6GAL1-induced sialylation of MUC4β altered its lectin binding and 
secretion. Both ST6GAL1 and MUC4β inhibited epithelial cell proliferation while promoting goblet 
cell differentiation. These in vivo and in vitro data provide strong evidence for a critical role for 
ST6GAL1-induced sialylation of MUC4β in epithelial dysfunction associated with T2-high asthma, 
thereby identifying specific sialylation pathways as potential targets in asthma.
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Secreted mucins, including MUC5AC and MUC5B, normally associated with O-linked glycosylation, 
have been widely investigated in airway disease, but less is known about membrane-bound mucins or the 
role of  N-glycosylation (10–13). MUC4, traditionally a tethered mucin reported to be upregulated in asth-
ma (14–16), comprises 2 subunits: the 850-kDa MUC4α, with a high degree of  O-glycosylation sites, but 
also a much smaller approximately 78- to 80-kDa MUC4β, which is suggested to have 18 potential N-gly-
cosylation sites (17, 18). N-glycosylation of  MUC4β is known to be induced by IL-4 and IL-9 in epithelial 
cell lines (19, 20), but the pattern, regulation, and functional effect are poorly studied.
Among many enzymes involved in the glycosylation and sialylation process, the β-galactoside α-2,6-sial-
yltransferase 1 (ST6GAL1) catalyzes terminal α 2,6-sialylation of  N-glycans to add sialic acid residues (21). 
It is present in plasma and lungs of  rats and humans, supporting its secretion (22–24). Previous gene expres-
sion profiling of  freshly brushed human airway epithelial cells (HAECs) identified an association between 
ST6GAL1 expression and the T2 biomarker fractional exhaled nitric oxide (FeNO) (25), supporting a poten-
tial T2 immune relationship. However, its target proteins (and their N-glycosylation) remain largely unknown.
We hypothesized that ST6GAL1 would promote MUC4β N-glycosylation and sialylation, both of  
which would be upregulated in asthma, particularly in association with T2 inflammation. In vitro, IL-13–
induced ST6GAL1 would promote terminal sialylation of  MUC4β N-glycans in HAECs, which would 
affect their differentiation and proliferation. This was evaluated by identifying ST6GAL1, MUC4β, and 
related pathways in freshly isolated, as well as cultured, HAECs and sputum supernatants from healthy 
control subjects (HC) and a range of  asthmatic patients to determine the expression, regulation, and func-
tional effect of  MUC4β N-glycosylation/sialylation in epithelial function and asthma.
Results
Demographics. Ex vivo sputum supernatants were obtained from 18 HC, 24 mild-moderate (MMA) par-
ticipants, and 26 severe asthma (SA) participants (Table 1). The groups did not differ by race, but SA 
patients were older, with the lowest forced expiratory volume in 1 second (FEV1) percentage predicted 
despite inhaled and oral corticosteroid use. SA patients also had the highest levels of  FeNO and blood and 
sputum eosinophils. Microarray data (GEO accessionGSE63142) were further analyzed (25). Quantitative 
real-time PCR (qRT-PCR) validation was performed on a subset of  7 HC, 13 MMA participants, and 9 SA 
participants (Supplemental Table 1; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.122475DS1), and Western blot was performed on separate freshly isolated HAECs 
(9 HC, 13 MMA, and 11 SA) (Supplemental Table 2). In vitro studies were performed on HAECs from 19 
HC, 29 MMA participants, and 28 SA participants (Table 2).
N-glycosylated MUC4β levels are higher in sputum supernatants from asthmatic subjects compared with HC. Human 
sputum is an accumulation of extracellular secretions and cells from lower airways (26). MUC4β was pres-
ent in sputum cell-free supernatants, and the 90-kDa isoform (by immunoblot) predominated. The intensity 
of the 90-kDa isoform was significantly higher in sputum supernatants from both MMA and SA participants 
compared with HC (Figure 1, A and B) and when controlling for age and sex. To determine whether the pre-
dominant 90-kDa isoform represented an N-glycosylated/sialylated isoform, sputum supernatants were treated 
with PNGase F to remove mature and immature N-glycans, neuraminidase to remove sialic acids from mature 
O- and N-linked glycans, or Endo H to remove only immature N-glycans. Following treatment, the 90-kDa band 
shifted primarily to a 65-kDa band when digested with PNGase F, consistent with the presence of approximately 
8 N-glycans (3 kDa per N-glycan). Neuraminidase treatment shifted the 90-kDa isoform to 78 kDa, a potential 
desialylated isoform of MUC4β, while Endo H had no effect (Figure 1C). Thus, the 90-kDa band represents an 
N-glycosylated isoform of MUC4β that contains mature N-glycans with terminal sialic acid residues.
T2 immune pathways are associated with N-glycosylated MUC4β levels ex vivo, and IL-13 enhances its N-gly-
cosylation in vitro. To begin to determine mechanisms driving the predominant 90-kDa MUC4β levels in 
asthmatic sputum, MUC4β was compared with levels of  T2 biomarkers (FeNO and blood and sputum 
eosinophils). The subjects were defined as “high” T2 on the basis of  a FeNO at ≥25 ppb (27, 28), blood 
eosinophils at ≥300 eosinophils/μl, or sputum eosinophils at ≥2% (29–32). The intensity of  the 90-kDa 
MUC4β isoform was significantly higher in the T2/blood and sputum eosinophil–high group but not high-
er in FeNO-high group as compared with the low groups (Figure 1D).
To determine whether the higher sputum N-glycosylated MUC4β in the presence of  T2 biomarkers could 
be due to induction by T2 cytokines, air-liquid interface–cultured (ALI-cultured) HAECs were treated with 
IL-13 (10 ng/ml) for 8 days, and apical supernatants and cell lysates were harvested for MUC4β expression. 
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IL-13 decreased the level of  78-kDa protein and increased the 90-kDa isoform levels but had inconsistent 
effects on a 150-kDa isoform (Figure 2, A and B). In contrast, IL-13 modestly but significantly decreased 
MUC4β mRNA (~20%) (Supplemental Figure 1). To confirm that the MUC4β-associated bands in vitro were 
N-glycosylated/sialylated isoforms, HAEC lysates were treated with PNGase F, neuraminidase, or Endo H. 
Similar to sputum, PNGase F shifted the 90-kDa band to a 65-kDa isoform. However, contrasting with spu-
tum, neither neuraminidase nor Endo H had any effect (Figure 2C). Thus, IL-13 affects the levels of  MUC4β 
isoforms in a posttranslational manner, while having a modest negative effect on mRNA.
N-glycosylation/sialylation functionally alters MUC4β, affecting its lectin binding and apical secretion. To deter-
mine the functional effect of  N-glycosylation of  MUC4β, the binding of  immunopurified MUC4β to lec-
tins, wheat germ agglutinin (WGA), Ulex europaeus agglutinin (UEA), Datura stramonium lectin (DSL), 
Sambucus nigra lectin (SNA), and Lycopersicon esculentum (tomato) lectin (LEL/LEA), was assessed by pull-
down assays with agarose-coupled lectins (33). IL-13 treatment for 8 days enhanced the fraction of  immu-
nopurified MUC4β binding to WGA (which binds to N-glycan chitobiose core structures as well as sialic 
acid), UEA (which binds terminal α-linked fucose residues) and SNA (which binds to sialic acid attached to 
terminal galactose in an α-2,6 configuration), while reducing binding to LEL (which binds polylactosamine 
present on the terminus of  either O-linked glycans or mature N-linked glycans) (Figure 2D). These data 
support both sialylation and fucosylation of  MUC4β by IL-13 and reduction in terminal polylactosamine.
To determine whether N-glycosylation/sialylation potentiated the secretion of  MUC4β (similar to 
that observed in sputum sol phase), apically secreted MUC4β was measured after 8 days in IL-13–treated 
HAECs. IL-13 consistently increased apical secretion of  the 90-kDa MUC4β, while having no consistent 
effect on the 150-kDa isoform (Figure 2E). To confirm that the secreted MUC4β-associated bands were 
N-glycosylated/sialylated isoforms, HAEC apical supernatants were treated with PNGase F, neuramin-
idase, or Endo H. Similar to sputum, PNGase F shifted the 90-kDa band to a 65-kDa isoform, while 
neuraminidase shifted the apical 90-kDa band to a 78 kDa isoform and Endo H had no effect (Figure 2F).
To confirm the effect of  N-glycans on MUC4β secretion, HAECs cultured for 8 days with IL-13 were 
metabolically pulsed with [35S] Met/Cys for 30 minutes and chased for 0, 3, and 24 hours before recovery 
of  cells and apical medium for MUC4β immunoprecipitation and analysis by SDS-PAGE. Radiolabeled 
proteins on SDS-PAGE were transferred to nitrocellulose for subsequent Western blotting. MUC4β was 
immunoprecipitated with the polyclonal anti-ASGP-2 (rat MUC4β) Ab. Radioactive imaging of  IL-13–
stimulated HAECs showed the presence of  both the 78-kDa MUC4β and 90-kDa N-glycosylated/sialylat-
ed isoforms after 30 minutes of  [35S]Met/Cys pulse (t = 0). As the chase period continued, the 78-kDa 
isoform decreased while the 90-kDa isoform increased, suggesting a shift to the more heavily sialylated 
isoform. The 90-kDa sialylated MUC4β isoform was measurable in the apical supernatant as early as 3 
hours after stimulation, while very little 78-kDa MUC4β was measurable. Overall, cell-associated 78-kDa 
Table 1. Demographics of ex vivo sputum supernatants
Healthy control Mild/moderate Severe Overall
(HC, n = 18) (MMA, n = 24) (SA, n = 26) P value
Sex (M/F) 10/8 5/19 12/14 0.052
Race (W/AA/others) 16/1/1 17/4/3 19/5/2 0.63
Age (yr) 30.3 (24.0–38.5) 33.8 (23.8–55.0) 50.2 (34.7–56.1) 0.0048
BMI (kg/m2) 23.0 (21.7–31.0) 27.4 (24.8–36.6) 27.8 (24.3–33.4) 0.067
Baseline FEV1 (% predicted) 98.0 (93.5–102.5) 89.5 (77.3–97.2) 70.5 (51.8–83.3) <0.0001
FeNO (ppb) 16.0 (11.6–22.6) 24.0 (17.0–48.5) 40.5 (30.3–68.4) 0.001
Blood eosinophils (/μl) 100 (100–114) 200 (100–413) 306(100–500) 0.0064
Sputum eosinophils (%) 0.2 (0.0–4.75) 0.3 (0.0–1.88) 3.7 (0.63–11.53) 0.0013
Serum IgE (kU/l) 74.0 (16.8–134.9) 129.3 (81.9–435.3) 138.4 (27.8–380.4) 0.07
ICS (yes/no) 0/18 18/6 26/0  <0.0001
OCS (yes/no) 0/18 2/22 22/4  <0.0001
Categorical variables were analyzed using Pearson χ2 tests. Continuous variables were not normally distributed and were analyzed using Wilcoxon/Kruskal-
Wallis tests and are presented as medians and interquartile range (25th–75th percentile). W, White; AA, African American; FeNO, fractional exhaled nitric 
oxide; ICS, inhaled corticosteroid; OCS, oral corticosteroid.
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MUC4β decreased over the chase period, while the 90-kDa MUC4β isoform increased in the apical super-
natants both by 35S imager and immunoblot (Supplemental Figure 2). The 150-kDa isoform was apparent 
in the cells and also disappeared with time but, interestingly, did not appear in the apical supernatant. Thus, 
N-glycosylation/sialylation of  MUC4β appears to be associated with increased apical secretion.
The sialyltransferase ST6GAL1 is higher in lung samples from asthmatics in association with T2 inflammation, and the 
results are mirrored by IL-13 stimulation in vitro. Lectin binding and neuraminidase treatments suggest MUC4β is an 
N-glycosylated mucin with terminal sialic acids modifications induced by T2 stimulation. Global epithelial gene 
profiling identified a strong correlation of ST6GAL1 with FeNO (ρ = 0.508, P = 0.000024) (25). Further analy-
sis showed that ST6GAL1 mRNA (microarray data) was significantly higher in asthmatics compared with HC 
and that severity and inhaled corticosteroid (ICS) use had only a minimal effect on differences (Supplemental 
Figure 3A). However, it was higher in all subjects with elevations in both T2 biomarkers, as previously defined 
(Supplemental Figure 3, B and C). These differences in ST6GAL1 by microarray were validated by qRT-PCR 
on freshly isolated epithelial cells, 80% of which overlapped with cells from subjects analyzed by microarray 
(Figure 3A). ST6GAL1 protein from freshly isolated HAECs was also higher in asthmatic patients compared 
with HC (overall P = 0.005; MMA vs. HC, P = 0.002; SA vs. HC, P = 0.017) (Figure 3B). Additionally, higher 
ST6GAL1 protein was associated with high FeNO (P = 0.028) and blood eosinophils (P = 0.039) (Figure 3C).
As ST6GAL1 has also been reported in plasma (34), ST6GAL1 protein was measured in sputum 
supernatants by immunoblotting and similarly was higher in asthmatic subjects as compared with HC 
(overall P = 0.023; MMA vs. HC, P = 0.012; SA vs. HC, P = 0.027), without differences in groups at dif-
ferent levels of  severity (Figure 3D). Importantly, higher ST6GAL1 protein in sputum was associated with 
high blood eosinophils (P = 0.02) but not with high sputum eosinophils (P = 0.19) and FeNO (P = 0.15) 
(Figure 3E). Not surprisingly, secreted ST6GAL1 protein in the sputum sol phase strongly correlated with 
the 90-kDa MUC4β isoform (Spearman’s ρ = 0.61, P = 0.001) (Figure 3F), suggesting that the relationship 
of  ST6GAL1 to sialylated MUC4β is due to the enzymatic activity of  ST6GAL1.
To determine whether IL-13 stimulation of  HAECs would recapitulate the ex vivo findings, ST6GAL1 
expression was measured. IL-13 increased expression of  ST6GAL1 mRNA (P = 0.0001) and protein (P = 
0.001) in whole cell lysates (Figure 4, A and B) as well as in apical supernatants (P = 0.001) (Figure 4C), 
mirroring the ex vivo findings. To determine the specificity of  IL-13 for ST6GAL1 expression, dose-re-
sponse studies were performed with other immune/inflammatory factors of  relevance to asthma, including 
TNF-α, IL-1β, IL-33, TSLP, and IFN-γ. Unlike the strong consistent effects of  IL-13, these cytokines did 
not consistently increase ST6GAL1 protein. However, higher doses of  TSLP generally induced ST6GAL1 
protein expression, although to a lesser degree than IL-13. In contrast, the type 1 cytokine IFN-γ consistently 
decreased expression of  ST6GAL1 protein with concomitant IL-13 stimulation (Supplemental Figure 4). 
Thus, only IL-13 and the T2-associated cytokine TSLP affected ST6GAL1 protein expression.
Table 2. Demographics of in vitro ALI-cultured HAECs
Healthy control Mild/moderate Severe Overall
(HC, n = 19) (MMA, n = 29) (SA, n = 28) P value
Sex (M/F) 8/11 8/21 11/17 0.14
Race (W/AA/others) 18/1/0 19/9/1  23/5/0 0.51 
Age (yr) 33.0 (24.6–41.0) 29.0 (24.3–40.8) 46.6 (39.8–53.5)  <0.0001
BMI (kg/m2) 31.0 (26.5–33.7) 26.3 (24.0–35.1) 33.8 (29.8–37.3) 0.04
Baseline FEV1 (% predicted) 92.0 (87.0–103.0) 84.0 (72.0–94.0) 64.5 (35.5–78.8)  <0.0001
FeNO (ppb) 17.0 (13.0–26.0) 32.8 (17.9–52.2) 32.5 (20.7–64.0)  <0.0001
Blood eosinophils (/μl) 192 (88–250) 300 (113–350) 300 (130–493) 0.29
Sputum eosinophils (%) 0.5 (0.001–4.8) 0.25 (0.001–2.45) 7.1 (1.0–13.9) 0.002
Serum IgE (kU/l)  43.0 (7.0–120.0) 135.3 (46.0–279.5) 96.0 (17.8–199.1) 0.2
ICS (yes/no) 0/19 17/11 25/3  <0.0001
OCS (yes/no) 0/19 1/28 20/8  <0.0001
Categorical variables were analyzed using Pearson χ2 tests. Continuous variables were not normally distributed and were analyzed using Wilcoxon/Kruskal-
Wallis tests and are presented as medians and interquartile range (25th–75th percentile). W, White; AA, African American; FeNO, fractional exhaled nitric 
oxide; ICS, inhaled corticosteroid; OCS, oral corticosteroid. 
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ST6GAL1 sialylates MUC4β under T2 conditions and alters its lectin binding. The strong correlation 
between sputum ST6GAL1 and MUC4β suggested an enzyme-substrate association. To confirm the effect 
of  ST6GAL1 on MUC4β sialylation, ST6GAL1 silencing was performed with Dicer siRNA transfec-
tion in the absence and presence of  IL-13. ST6GAL1 knockdown decreased IL-13–induced ST6GAL1 
mRNA (P = 0.001) and protein (P = 0.0005) (Supplemental Figure 5, A and B, and Figure 5A). Impor-
tantly, ST6GAL1 knockdown markedly decreased the ratio of  the 90-kDa isoform to 78-kDa MUC4β 
in the presence of  IL-13 (P = 0.008) (Figure 5, A and B) as well as the ratio of  the 150-kDa isoform 
to 78-kDa MUC4β (P = 0.016) (Supplemental Figure 5C) in whole cell lysates. In addition, ST6GAL1 
knockdown reduced the binding of  immunopurified MUC4β to WGA, UEA, and SNA, while it recov-
ered the LEL-binding capacity (Figure 5C), essentially reversing the effects of  IL-13 reported in Figure 
2D. As expected, ST6GAL1 knockdown inhibited secretion of  apical ST6GAL1 and 90-kDa MUC4β 
in the presence of  IL-13, supporting the necessity of  N-glycosylation for secretion (Figure 5D and Sup-
plemental Figure 5D). Thus, IL-13 increases MUC4β sialylation through ST6GAL1 enzymatic activity, 
which substantially alters its structure, function, and location.
Antiproliferative effects of  T2 inflammation may be mediated by ST6GAL1 in vivo and in vitro. Evidence exists 
for ongoing epithelial damage and repair in asthma (35, 36). ST6GAL1 mRNA negatively correlated with the 
cell cycle protein cyclin D1 (CCND1) in the epithelial microarrays (r = –0.39, P < 0.0001), potentially indi-
cating an effect on cell proliferation. To confirm the hypothesis that ST6GAL1 has antiproliferative effects on 
HAECs, the effect of  ST6GAL1 knockdown on pAkt/Akt, CCND1, and the proliferation marker Ki67 was 
assessed (37, 38). PI3K/Akt is one of  the most important signaling pathways for cell proliferation, cell cycle, 
and apoptosis (39). In order to verify whether IL-13 or IL-13–induced ST6GAL1 was associated with PI3K/
Akt signaling or cell cycle, ST6GAL1 knockdown was performed and proliferation markers were analyzed.
IL-13 has been reported to increase Akt phosphorylation following acute (2-hour) exposure (40). Acute 
IL-13 stimulation (from 0.25–24 hours) similarly increased pAkt and CCND1 (Supplemental Figure 6). In 
sharp contrast, chronic IL-13 stimulation for 8 days markedly decreased pAkt (relative to total Akt) (P = 
0.021, IL-13 vs. unstimulated) and CCND1 (relative to GAPDH) (P = 0.0013, IL-13 vs. unstimulated) (Fig-
Figure 1. N-glycosylated 90-kDa MUC4β was higher in asthmatic sputum supernatants and associated with a T2 
signature. (A and B) Western blot and densitometry of MUC4β (18 HC, 24 MMA, 26 SA). Since there were no loading 
controls for sputum supernatant, the same amount of 40 μg total proteins were loaded for each sample, and 1 internal 
control sample was loaded for each gel. (C) Deglycosylation with PNGase F, neuraminidase (Neur.), and Endo H (n = 3). 
Untreated samples were added reaction buffer without above enzymes. (D) The 90-kDa MUC4β isoform was associated 
with the T2 inflammation markers blood and sputum eosinophils but not FeNO. The data are presented as median 
with interquantile range. Wilcoxon tests identified the overall differences among the groups. When overall P ≤ 0.05, 
intergroup comparisons were further assessed using Wilcoxon signed rank. One-way analysis Wilcoxon test was used 
for 2 independent group comparison. 
6insight.jci.org   https://doi.org/10.1172/jci.insight.122475
R E S E A R C H  A R T I C L E
ure 5E). Interestingly, ST6GAL1 knockdown reversed IL-13–attenuated relative pAkt and CCND1 protein 
(pAkt/Akt, P = 0.014; CCND1/GAPDH, P < 0.0001, siST6GAL1 vs. scramble). ST6GAL1 knockdown 
also increased CCND1 in the absence of  IL-13 (P = 0.0002, siST6GAL1 vs. scramble) (Figure 5E), sug-
gesting that the effect did not depend on IL-13. The functional effect of  the higher pAkt and CCND1 levels 
induced by ST6GAL1 knockdown was confirmed by the parallel restoration of  Ki67 immunofluorescent 
staining (unstimulated, P = 0.023; IL-13, P = 0.007, siST6GAL1 vs. scramble) (Figure 5, F and G).
Knockdown of  ST6GAL1 decreases MUC5AC and the goblet cell–associated transcription factor FOXA3. 
FOXA3 induces MUC5AC and goblet cell metaplasia in response to infection or T2 stimulation (41, 42). 
To determine whether ST6GAL1 affected goblet cell differentiation, the effect of  ST6GAL1 knockdown on 
expression of  MUC5AC and FOXA3 mRNA/protein under IL-13 conditions was evaluated. ST6GAL1 
knockdown reduced mRNA/protein expression of  MUC5AC and FOXA3 (MUC5AC mRNA, P = 0.014; 
secreted MUC5AC protein, P = 0.002; FOXA3 mRNA, P = 0.002; FOXA3 protein, P = 0.035) (Figure 6), 
supporting a critical role for ST6GAL1 in goblet cell differentiation via FOXA3 and MUC5AC.
ST6GAL1-induced MUC4β N-glycosylation is necessary for IL-13–induced effects on HAEC proliferation and differ-
entiation. To confirm whether the effects of  ST6GAL1 were through MUC4β sialylation, MUC4β knockdown 
was performed in the presence and absence of  IL-13. Silencing MUC4β preferentially decreased the ratio 
of  the 90-kDa sialylated isoform to 78-kDa MUC4β (P = 0.03, siMUC4β vs. scramble) and the ratio of  the 
150-kDa isoform to the 78-kDa MUC4β (P = 0.03, siMUC4β vs. scramble) in the presence of  IL-13 (Figure 
Figure 2. Effects of IL-13 on MUC4β N-glycosylation/secretion and lectin-binding capacity in 8-day ALI-cultured HAECs. (A and B) Representative West-
ern blot of 78-, 90-, 150-kDa MUC4β isoforms influenced by IL-13 (indexed to GAPDH) (n = 37). (C) Deglycosylation with PNGase F, neuraminidase (Neur.), 
and Endo H in IL-13–stimulated HAECs (n = 3). (D) Representative Western blot of lectin (WGA, UEA, DSL, SNA, and LEL) binding of 90-kDa MUC4β in the 
absence and presence of IL-13 for 8 days (n = 3). (E) Representative Western blot of apical supernatant MUC4β isoforms in ALI-cultured HAECs. (F) Degly-
cosylation with PNGase F, neuraminidase, and Endo H in IL-13–stimulated apical supernatant (n = 3). Nonparametric paired t test identified the difference 
between IL-13 and unstimulated condition.
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7A and Supplemental Figure 7), suggesting a preferential effect on the most highly expressed (N-glycosylat-
ed) forms, including the 90-kDa isoform. Similar to the effects of  ST6GAL1 knockdown, silencing MUC4β 
increased pAkt (relative to Akt) (IL-13 condition, P = 0.034), CCND1 (relative to GAPDH) (P = 0.007 for 
unstimulated and P = 0.008 for IL-13 stimulation) (Figure 7B), and Ki67+ immunofluorescent staining in the 
absence and presence of  IL-13 (unstimulated, P = 0.049; IL-13, P < 0.0001, siMUC4β vs. scramble) (Figure 7, 
C and D). Due to limited primary HAEC numbers, knockdown experiments were set up using a single culture 
well treated with the same scramble control. Cells from this well were utilized as the control condition for 
both siST6GAL1 and siMUC4β experiments (Figure 5F and Figure 7C).
Figure 3. The levels of ST6GAL1 mRNA/protein and association with T2 inflammation in freshly isolated epithelial cells and sputum supernatant 
among HC, MMA, and SA. (A) ST6GAL1 mRNA by qRT-PCR in freshly isolated epithelial cells (7 HC, 13 MMA, 9 SA). (B) Representative Western blot and 
densitometry of ST6GAL1 protein (9 HC, 13 MMA, and 11 SA) in freshly isolated epithelial cells. (C) Presence of T2 inflammation (FeNO and blood eosin-
ophils) associated with increased epithelial cell ST6GAL1 protein. (D) Representative Western blot and densitometry of sputum supernatant ST6GAL1 
protein (6 HC, 7 MMA, 13 SA). (E) Sputum supernatant ST6GAL1 protein was associated with blood eosinophils but not sputum eosinophils and FeNO. (F) 
ST6GAL1 protein positively correlated with 90-kDa MUC4β protein in sputum supernatant. The data are presented as median with interquantile range. 
Wilcoxon tests identified the overall differences for multiple comparisons, followed by Wilcoxon each pair comparison when overall P ≤ 0.05. One-way 
analysis Wilcoxon test was used for independent comparison between 2 groups. Spearman’s ρ was applied for nonparametric correlation analysis.
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Similar to silencing ST6GAL1, knockdown of  MUC4β decreased mRNA/protein expression of  
MUC5AC and FOXA3 (MUC5AC mRNA, P = 0.006; secreted MUC5AC protein, P = 0.03; FOXA3 
mRNA, P = 0.02; FOXA3 protein, P = 0.047) (Figure 8). Thus, MUC4β knockdown recapitulates the 
differentiation and proliferation effects of  ST6GAL1 knockdown, suggesting that posttranslationally mod-
ified MUC4β plays an intermediary role in these functional changes.
Discussion
It has become increasingly apparent that posttranslational modifications, such as N- glycosylation and 
sialylation, are essential for regulating biologic responses. Results from this study confirm a critical role for 
the sialyltransferase ST6GAL1 to promote the terminal sialylation of  MUC4β, resulting in subsequent gob-
let cell differentiation and antiproliferative responses in airway epithelium. Sialylated MUC4β is increased 
ex vivo in sputum supernatants, generally appears at higher levels in T2-high participants, and is concor-
dant with high levels of  ST6GAL1 in both sputum supernatant and freshly isolated HAECs. These ex vivo 
results correspond with the ability of  IL-13–induced ST6GAL1 to increase MUC4β sialylation in ALI-cul-
tured HAECs. Importantly, N-glycosylated/sialylated MUC4β enhances specific lectin (WGA and SNA) 
binding, while decreasing LEL binding, thus altering its function and secretion. ST6GAL1 knockdown 
reverses these effects, restoring HAEC proliferation and inhibiting goblet cell differentiation. These results 
uniquely define a central role for N-glycosylation/sialylation in epithelial cell differentiation, with implica-
tions for asthma and more broadly in other epithelial processes, including cancer.
Asthma has long been characterized by mucin abnormalities (43). Mucins are large family of  high 
MW, heavily glycosylated proteins produced by epithelial cells (14). MUC4β is the N-glycosylated trans-
Figure 4. IL-13–induced ST6GAL1 mRNA and protein expression in intracellular and apical supernatants 
in ALI-cultured HAECs. (A) IL-13 increased ST6GAL1 mRNA expression. (B) Representative Western blot and 
densitometry of ST6GAL1 in IL-13–stimulated HAECs (indexed to GAPDH). (C) Representative Western blot and 
densitometry of apical supernatant ST6GAL1 (indexed to whole cell lysates GAPDH; since there were no loading 
controls for apical supernatant and the cells directly controlled secretion). Nonparametric paired t test identified 
the difference between IL-13 and unstimulated condition.
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Figure 5. ST6GAL1 knockdown decreased sialylated MUC4β but enhanced proliferative signaling in ALI-cul-
tured HAECs. (A) Representative Western blot of ST6GAL1 and MUC4β after ST6GAL1 knockdown in HAECs. (B) 
The ratio of 90-kDa/78-kDa MUC4β was decreased by ST6GAL1 knockdown in IL-13 condition. (C) Representative 
Western blot of MUC4β lectin pulldown after ST6GAL1 knockdown in IL-13–stimulated HAECs for 8 days (n = 3). 
(D) Representative Western blot of apical secreted ST6GAL1 and MUC4β in the absence and presence of IL-13 (n 
= 5). (E) Representative Western blot and densitometry of pAkt/Akt and CCND1/GAPDH by ST6GAL1 knockdown 
in the absence and presence of IL-13 for 8 days. (F and G) Representative Ki67 immunofluorescent staining and 
quantification by ST6GAL1 knockdown in the absence and presence of IL-13 for 8 days in ALI-cultured HAECs (n = 
3). Original magnification, ×600. Nonparametric paired t test identified the difference between IL-13 and unstim-
ulated condition and siST6GAL1 vs. scramble.
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membrane subunit of  MUC4, which has been suggested to be both membrane bound and secreted (44, 
45). MUC4β has multiple potential N-glycosylation sites (46), consistent with the multiple MW isoforms 
reported here (78, 90, and 150 kDa). Only an approximately 140-kDa isoform has previously been report-
ed, in response to IL-4 and IL-9 in human bronchoalveolar carcinoma cell lines (19, 20), with limited data 
to suggest an indirect role for neutrophil elastase in MUC4β N-glycosylation (47). However, no specific 
N-glycosylating enzymes have been identified and the functional effect has not been outlined in HAECs.
In the current study, IL-13 most consistently induced a 90-kDa MUC4β isoform in primary HAECs, 
with the 150 kDa isoform inconsistently altered. Importantly, this 90-kDa isoform was selectively secreted 
both into cultured HAEC apical supernatants and asthmatic subject sputum, with higher levels preferen-
tially associated with elevations in T2 biomarkers. PNGase F decreased the MW of  both the secreted and 
intracellular glycoproteins, while neuraminidase only reduced the MW of  the secreted form, suggesting 
that sialylation was functionally contributing to its secretion. To confirm the presence of  sialic acid residues 
on the 90-kDa MUC4β isoform, lectin pulldown studies were performed. The highly specific lectin binding 
to SNA demonstrated the characteristic presence α 2, 6 sialic acid residues on the 90-kDa isoform and was 
consistent with the neuraminidase studies.
However, in addition to affecting secretion, sialylation is likely to have other effects. Sialylation can mask 
biological recognition sites or represent specific recognition epitopes as ligands, all widely changing immune 
responses (48, 49). Previous reports showed that sialylation of N-glycans was responsible for apical delivery of  
a model mucin-like protein (endolyn) to the surface of polarized MDCK cells — the sialylation allowed interac-
tion with galectin-9 that crosslinks the protein and retains it on the cell surface (50). This suggests that N-glycan 
sialylation can have substantial effects on protein expression and stability (51, 52). Sialylation of MUC1, for 
instance, influences cell-cell and cell-matrix adhesion, cell motility, and host cell–pathogen interactions (53, 54). 
Thus, the effect of sialylation of MUC4β on epithelial differentiation is in-line with that shown in previous 
Figure 6. ST6GAL1 knockdown attenuated T2-caused goblet cell differentiation in ALI-cultured HAECs. (A and B) 
Knockdown of ST6GAL1 decreased the MUC5AC mRNA by qRT-PCR and protein by ELISA. (C) Knockdown of ST6GAL1 
decreased FOXA3 mRNA by qRT-PCR. (D) Representative Western blot of FOXA3 and densitometry (index to GAPDH). 
Nonparametric paired t test identified the difference between siST6GAL1 and scramble.
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studies. Importantly, IL-13 appears to contribute to the addition of alternative N-glycosylation effects as well, as 
it enhances UEA binding of MUC4β, consistent with fucosylation, while decreasing terminal polylactosamine 
processing of N-glycans, as demonstrated by reduced LEL binding. Further studies of the precise glycoprotein 
interactions driving these additional functional changes to MUC4β and their functional effect will be needed.
Given the evidence for the addition of  α 2,6-sialic acid residues to MUC4β, it is perhaps not surprising 
that ST6GAL1 was found to contribute to this process. ST6GAL1, highly expressed in airway epithelial 
cells (55), was identified on our previous microarrays as one of  several N-glycosylating enzymes strongly 
correlated with the T2 biomarker FeNO in human airways (25). ST6GAL1 broadly distributes in different 
tissues and is necessary for the addition of  almost all α 2,6-sialylated N-glycans (56). The current results 
add to these by reporting higher ST6GAL1 mRNA and protein in asthmatic HAECs and sputum in associ-
ation with elevated T2 biomarkers. The ex vivo relationship to T2 inflammation was then mechanistically 
confirmed in vitro, as IL-13 strongly induced intracellular and secreted ST6GAL1 protein. The modestly 
variable relationships of  ST6GAL1 or MUC4β with T2 biomarkers (FeNO, blood/sputum eosinophils) 
suggest other stimuli may contribute to their expression. In fact, other inflammatory factors (TNF-α, IL-1β, 
Figure 7. Knockdown of MUC4β primarily decreased its N-glycosylated/sialylated isoform but increased proliferative signaling in 8-day ALI-cultured 
HAECs in the absence or presence of IL-13. (A) Representative Western blot of MUC4β and densitometry of MUC4β ratios (90 kDa/78 kDa) after MUC4β 
knockdown. (B) Representative Western blot and densitometry of pAkt (indexed to total Akt) and CCND1 (indexed to GAPDH) by MUC4β knockdown. (C 
and D) Representative Ki67 immunofluorescent staining and quantification by MUC4β knockdown in the absence and presence of IL-13–stimulated HAECs 
(n = 3). For transfection experiments, the same scramble siRNA was utilized as a negative control well/condition for both siST6GAL1 and siMUC4β. There-
fore, the Ki67 immunofluorescent images for scramble siRNA are identical to the images in Figure 5F. Original magnification, ×600. Nonparametric paired 
t test identified the difference between siMUC4β and scramble.
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IL-33, and IFN-γ) had less or no stimulatory effect on ST6GAL1, suggesting that T2 cytokines are likely 
the most important inducer for ST6GAL1 protein. A potential stimulatory role for TSLP in this expression 
requires further study. While in vitro and ex vivo data support a stimulatory role for T2 and related cyto-
kines in the upregulation of  ST6GAL1, the actual cytokine or mixture of  cytokines driving the increase in 
ST6GAL1 expression in individual patients cannot be determined from these studies.
Altered glycosylation is known to be a common feature of  epithelial-derived cancer cells, where aberrant 
glycosylation interferes with regulation of  cell adhesion, migration, and proliferation and links to tumor ini-
tiation, progression, and metastasis (48). The effect of  specific N-glycosylation events varies, with some pro-
moting tumor progression, while others limit progression/metastases. Elevated expression of  ST6GAL1 has 
previously been observed in multiple types of  adenocarcinomas and linked to both worsened and improved 
outcomes (57, 58). These contradictory observations may relate to differences in cancer mucin expression 
and/or effect on PI3K/Akt-related proliferation pathways (59, 60). In primary differentiated noncancerous 
HAECs, ST6GAL1 inhibited PI3K/Akt pathways and associated proliferation signaling in the presence of  
IL-13, while ST6GAL1 knockdown restored a more proliferative/progenitor-like cell type. These results con-
trast with cancerous cells, which also express high levels of  ST6GAL1. Cancerous cells can have similarities 
with human induced pluripotent stem cells, which continuously divide until a stimulus is received to exit 
the division cycle and cell differentiation occurs (61). High ST6GAL1 expression was recently associated 
with human induced pluripotent stem cells, they were even required for their perpetuation (62), such that 
ST6GAL1 could play distinctly different roles, depending on the differentiation state of  the cell.
The evolving data on ST6GAL1 in asthma yield conflicting views. Overexpression of  ST6GAL1 was 
reported to promote TGF-β–induced epithelial-mesenchymal transition via glycosylation of  multiple pro-
teins (60). While epithelial-mesenchymal transition of  HAECs is controversial, IL-13 increases TGF-β2 
Figure 8. Knockdown of MUC4β decreased T2-induced goblet cell differentiation in 8-day IL-13–stimulated ALI-cul-
tured HAECs. (A and B) Knockdown of MUC4β decreased the MUC5AC mRNA by qRT-PCR and protein by ELISA. (C) 
Knockdown of MUC4β decreased FOXA3 mRNA by qRT-PCR. (D) Representative Western blot and densitometry of 
FOXA3 (index to GAPDH) in MUC4β-silenced HAECs under IL-13 conditions. Nonparametric paired t test identified the 
difference between siMUC4β and scramble.
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expression in HAECs, although a role for ST6GAL1 remains to be determined (63). The data presented 
here show ST6GAL1 upstream of  FOXA3 in orchestrating goblet cell differentiation, widely observed in 
asthma, and at least partially dependent on MUC4β sialylation (10, 42). Similarly, increased expression of  
ST6GAL1 has been reported on T2 lymphocytes (64). However, a global ST6GAL1-knockout mouse study 
demonstrated worsened eosinophilic inflammation to allergen challenge (65). Effects on airway hyperres-
ponsiveness were not reported in that study, and further targeted deletion studies will be required.
This study does not define the specifics of  the structural changes to MUC4β. While ST6GAL1 is a spe-
cific sialyltransferase that alters the glycostructure and subsequent biology of  MUC4β, most likely through 
addition of  sialic acid residues to N-glycans, it is conceivable that other glycosylating enzymes, and even 
alterations in O-glycosylation, may also have a functional effect, and they await further study. This is fur-
ther emphasized by the lectin-binding studies reported here, which suggest MUC4β is also fucosylated. The 
enzyme controlling that reaction, the actual structural change or functional effect, is not yet known, although 
a reduction in UEA binding with ST6GAL1 knockdown suggests ST6GAL1 itself  may be involved.
Limitations of  this study include the possible off-target effects of  the ST6GAL1 or MUC4β DsiRNA. 
However, the results from ST6GAL1 and MUC4β knockdown appear to be highly complementary. The 
pathway by which MUC4β affects PI3K/Akt signaling and proliferation also remains unclear. Whether 
there are differences in the target proteins for the surface-bound versus secreted forms of  these proteins is 
also not clear but is certainly likely. For example, secreted ST6GAL1 could alter airway luminal immuno-
globulin glycosylation status, substantially changing its function (66).
Taken together, these results identify ST6GAL1 as the primary driver for the terminal sialylation of  
MUC4β N-glycans, and the apical secretion of the glycoprotein, both in vitro and in vivo, predominantly in 
T2-high asthma. Most importantly, ST6GAL1 and MUC4β orchestrate IL-13–induced goblet cell differentia-
tion, cell cycling, and proliferation upstream of FOXA3, identifying this axis as an epithelial target for asthma.
Methods
Subjects. Participants were 18–65 years old and enrolled in the Severe Asthma Research Program 
(SARP) and the Electrophilic Fatty Acid Derivatives and Immune Epithelial Interactions in Severe 
Asthma studies. Participants were nonsmokers or had a smoking history of  less than 5 packs year, with 
no smoking in last the year. HC had normal lung function, without a history of  any acute or chronic 
respiratory illness. SA was defined using the 2014 European Respiratory Society-American Thoracic 
Society guidelines (67). Patients with MMA had an FEV1 equal or greater than 75% predicted and 
were on no ICS or a low/medium dose, with or without a second controller (68). All participants 
were extensively characterized, including spirometry, FeNO, and blood/sputum eosinophils (68, 69). 
T2-high inflammation was identified as FeNO levels above 25 ppb (T2/FeNO high), blood eosinophils 
above 300 eosinophils/μl (T2/Eos. high), or sputum eosinophils above 2% (29, 31, 32, 69). T2-low 
inflammation was defined as levels below all of  these cut-off  points.
Bronchoscopy and sample processing. Bronchoscopy with epithelial brushings was performed following the 
SARP Manual of  Procedures as previously described (68, 70). Induced sputum was processed according to 
SARP protocol, using a slightly modified method of  Fahy et al. (71).
Primary HAEC culture under ALI and DsiRNA transfection. Bronchoscopically obtained HAECs 
placed in submerged culture were proliferated and then passaged onto Transwell plates and cultured 
under ALI for 8 days in the absence and presence of  IL-13 (R&D Systems, catalog 213-ILB-025, 10 
ng/ml) as previously described (63, 72). Apical supernatants were collected after incubating with 
fresh medium at 37°C for 1 hour, while cells were harvested for mRNA and protein analysis. Mean-
while, similar to the initial experiments with IL-13, other immune/inflammatory cytokines (R&D 
Systems) (TNF-α, catalog 210-TA-010; IL-1β, catalog 201-LB-005; IL-33, catalog 3625-IL-010; and 
TSLP, catalog 1398-TS-010) in different doses were applied to measure ST6GAL1 expression in 
ALI-cultured HAECs. For IFN-γ (catalog 285-IF-100), the HAECs were pretreated with IL-13 (1 
ng/ml) for 6 days and then further stimulated with either IL-13 or different doses of  IFN-γ (1, 10, 
and 100 ng/ml) for 2 days before collecting the cells.
Transfection of  ST6GAL1 or MUC4β DsiRNA was performed as previously described with slight 
modification (73). In general, scrambled (negative control) or ST6GAL1/MUC4β DsiRNA (siST6GAL1/
siMUC4β) was mixed with Lipofectamine RNAiMAX (catalog 13778150, Invitrogen) in Opti-MEM I (cat-
alog 31-985-070, Gibco) incubated at room temperature for 20 minutes and added to full media, including 
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200,000 cells per well. Following gentle mixing, the siRNA-RNAiMAX-cell mixture was added to the 
Transwell insert (final siRNA concentration 50 nM) and incubated at 37°C in a 5% CO2 incubator. After 
reaching confluency at 24 hours, IL-13 was added to the lower chamber every 48 hours with each media 
change. At days 8, apical supernatant was harvested to measure apical ST6GAL1 and MUC4β protein and 
cells harvested for mRNA/protein analysis.
Microarray mRNA data analysis. Our published microarray profile from freshly brushed HAECs report-
ed that ST6GAL1 positively correlated with FeNO (25). The previously reported gene expression data 
(National Center for Biotechnology Information’s GEO database; accession GSE63142) were utilized to 
better establish the relationship between ST6GAL1 and FeNO and blood eosinophils. Gene expression of  
ST6GAL1 (probe: A24_P397043) was also compared among HC, MMA, and SA. ST6GAL1 mRNA/
protein expression was validated by qRT-PCR and Western blot using freshly isolated HAECs.
qRT-PCR. mRNA expression was determined by qRT-PCR performed on the ABI prism 7900 sequence 
detection system (Applied Biosystems). Primers and probes were purchased from Applied Biosystems 
(Assays on Demand; ST6GAL1: Hs00949382_m1; MUC4β: Hs00366414_m1; CCND1: Hs00765553_m1; 
MUC5AC: Hs01365616_m1; FOXA3: Hs00270130_m1). The mRNA levels were determined relative to β 
glucuronidase (GUSB: Hs99999908_m1) using the ΔCt method.
SDS-PAGE and Western blotting. The expression of  ST6GAL1 (1:1000, catalog AF5924, R&D Sys-
tems), MUC4β (1:1000, catalog NBP1-52193, Novus), CCND1 (1:500, catalog ab134175, Abcam), 
phosphorylated Akt (1:1000, catalog 9271S, Cell Signaling) and total Akt (1:1000, catalog 9272S, Cell 
Signaling), and FOXA3 (1:100, catalog sc-5361, Santa Cruz) was measured by Western blotting on 
4%–12% SDS-PAGE (Invitrogen). GAPDH (1:1000, catalog NB 300-320, Novus) or β-Actin (1:2000, 
catalog A5441, MilliporeSigma) served as a loading control. Amersham imager 600 (GE Healthcare 
Life Sciences) with SuperSignal West Femto Maximum Sensitivity Substrate (catalog 34096, Thermo 
Fisher) was utilized to develop the blots. Sputum supernatant ST6GAL1 or MUC4β levels were nor-
malized by loading 40 μg of  total protein per sample. As no loading control was available for sputum 
supernatants, a single HC sputum sample was run on all the gels, and ST6GAL1 or MUC4β levels 
were indexed to it. The apical supernatant ST6GAL1 or MUC4β was indexed using the loading con-
trol from whole cell lysates.
Glycosidase digestion reactions. PNGase F (catalog P0704S), neuraminidase (catalog P0720S), and Endo 
H (catalog P07025) were purchased from New England Biolabs. Glycosidase digestion reactions were 
performed on sputum supernatant, ALI-cultured HAECs lysates, and apical supernatant based on the 
products’ protocol. The samples were denatured, digested by glycosidases, and resolved on 4%–12% SDS-
PAGE and blotted with anti-MUC4β Ab. For control reactions buffer was substituted for the enzyme. The 
untreated and enzyme-treated samples were split from the same sample, so no loading control was needed 
for the supernatant or apical supernatants.
Pulse-chase protein labeling. Following 8 days of  ALI culture, cells in medium (with or without IL-13) 
lacking methionine (Met) or cysteine (Cys), were then metabolically pulsed labeled for 30 minutes in 0.5 ml 
of  the same medium containing [35S] Met/Cys (catalog NET027X250UC, Perkin Elmer); then chased for 
0, 3, and 24 hours with nonradioactive medium; and washed. Apical supernatants and whole cell lysates 
were harvested for immunoprecipitation using anti-MUC4β Ab (Novus). SDS-PAGE was performed, pro-
teins were transferred to nitrocellulose, and radiolabeled bands were identified with a Bio-Rad Imager and 
then blotted with anti-MUC4β Ab. Radiolabeling was essentially carried out as previously described (74).
Lectin-binding assays. Lectin-binding assays were performed on detergent extracts from cells grown with 
and without IL-13 or siST6GAL1 for 8 days. After immunoprecipitation using anti-rat ASGP-2 Ab (pro-
vided by Kermit L. Carraway, University of  Miami, Coral Gables, Florida, USA), samples were eluted in 
1% SDS, diluted with buffer (0.5% Triton X-100 in 10 mM HEPES, pH 7.4, 150 mM NaCl), and incubated 
with 50 μl of  the indicated lectin-agarose beads (WGA, UEA, DSL, SNA, and LEL) by end-over-end 
mixing at 4°C overnight, washed with buffer, analyzed by SDS-PAGE, and blotted with anti-MUC4β Ab. 
WGA, DSL, SNA and LEL were from Vector Laboratories, and UEA was from EY Laboratories. Lec-
tin-binding studies were carried out as previously described (33).
Immunofluorescence staining for Ki67 and quantification. ALI-cultured HAECs were transit transfected with 
siST6GAL1 or siMUC4β in the absence or presence of IL-13 for 8 days and then fixed on 2% paraformalde-
hyde, permeabilized with 0.1% Triton X-100, blocked by blocking serum, and then incubated with anti-Ki67 Ab 
(1:1000, catalog ab15580, Abcam), followed by incubation with Alexa Fluor 594 donkey anti-rabbit IgG (1:400, 
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catalog A21207, Invitrogen). DAPI (1:1000) was applied for nuclear staining. No primary Ab control was per-
formed as negative control. The sections were observed under Nikon A1 confocal microscope. To quantify Ki67 
in immunofluorescent staining, the percentage of positive Ki67 cells was calculated based on the total numbers 
of nuclei stained with DAPI.
Semiquantitative MUC5AC ELISA. MUC5AC protein was measured from apical supernatant in ALI-cul-
tured HAECs using a semiquantitative sandwich ELISA. All results are given in relative arbitrary units/ml (42).
Statistics. Statistical analysis was performed with JMP SAS software (SAS Institute). Data were analyzed 
for normality. Most data were not normally distributed and are presented as medians, with 25%–75% inter-
quartile range. Wilcoxon tests identified the overall significant differences among the groups or conditions. 
When a significant difference was observed, intergroup comparisons were further assessed using Wilcoxon 
signed rank and a Bonferroni correction for multiple comparisons. For in vitro experiments, nonparamet-
ric signed-rank tests compared mRNA or protein levels for paired conditions of  ST6GAL1, MUC4β, pAkt, 
CCND1, MUC5AC, and FOXA3. Pearson correlation was used for normally distributed data, and Spear-
man for correlations was used for nonparametric data. Quantification of  immunoblots was performed using 
ImageJ software (NIH). P < 0.05 was considered statistically significant. Student’s 2-tailed t test was used.
Study approval. The study was approved by the individual IRBs located at the University of Wisconsin, the 
Cleveland Clinic, Wake Forest University, as well as the University of Pittsburgh. All participants provided 
written informed consent prior to inclusion in the study and were identified by different numbers, not by names.
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